Raloxifene and alendronate containing thin mesoporous titanium oxide films improve implant fixation to bone

N. Harmankaya; J. Karlsson; A. Palmquist; M. Halvarsson; K. Igawa; M. Andersson; P. Tengvall

doi:10.1016/j.actbio.2013.02.040

Raloxifene and alendronate containing thin mesoporous titanium oxide films improve implant fixation to bone

N. Harmankaya, J. Karlsson, A. Palmquist, M. Halvarsson, K. Igawa, M. Andersson, P. Tengvall

Research output: Contribution to journal › Article › peer-review

61 Citations (Scopus)

Abstract

This study tested the hypothesis that osteoporosis drug-loaded mesoporous TiO₂ implant coatings can be used to improve bone-implant integration. Two osteoporosis drugs, Alendronate (ALN) and Raloxifene (RLX), were immobilized in nanoporous oxide films prepared on Ti screws and evaluated in vivo in rat tibia. The drug release kinetics were monitored in vitro by quartz crystal microbalance with dissipation and showed sustained release of both drugs. The osteogenic response after 28 days of implantation was evaluated by quantitative polymerase chain reaction (qPCR), removal torque, histomorphometry and ultrastructural interface analysis. The drug-loaded implants showed significantly improved bone fixation. In the case of RLX, stronger bone-remodelling activity was observed compared with controls and ALN-loaded implants. The ultrastructural interface analysis revealed enhanced apatite formation inside the RLX coating and increased bone density outside the ALN coating. Thus, this novel combination of a thin mesoporous TiO₂ carrier matrix and appropriate drugs can be used to accelerate implant fixation in trabecular bone.

Original language	English
Pages (from-to)	7064-7073
Number of pages	10
Journal	Acta Biomaterialia
Volume	9
Issue number	6
DOIs	https://doi.org/10.1016/j.actbio.2013.02.040
Publication status	Published - Jun 2013
Externally published	Yes

Keywords

Bisphosphonate
Drug delivery
Mesoporous
Raloxifene
Titanium

ASJC Scopus subject areas

Biotechnology
Biomaterials
Biochemistry
Biomedical Engineering
Molecular Biology

Access to Document

10.1016/j.actbio.2013.02.040

Cite this

@article{a7be138ff19c4e169bd4ce74ff33315c,

title = "Raloxifene and alendronate containing thin mesoporous titanium oxide films improve implant fixation to bone",

abstract = "This study tested the hypothesis that osteoporosis drug-loaded mesoporous TiO2 implant coatings can be used to improve bone-implant integration. Two osteoporosis drugs, Alendronate (ALN) and Raloxifene (RLX), were immobilized in nanoporous oxide films prepared on Ti screws and evaluated in vivo in rat tibia. The drug release kinetics were monitored in vitro by quartz crystal microbalance with dissipation and showed sustained release of both drugs. The osteogenic response after 28 days of implantation was evaluated by quantitative polymerase chain reaction (qPCR), removal torque, histomorphometry and ultrastructural interface analysis. The drug-loaded implants showed significantly improved bone fixation. In the case of RLX, stronger bone-remodelling activity was observed compared with controls and ALN-loaded implants. The ultrastructural interface analysis revealed enhanced apatite formation inside the RLX coating and increased bone density outside the ALN coating. Thus, this novel combination of a thin mesoporous TiO2 carrier matrix and appropriate drugs can be used to accelerate implant fixation in trabecular bone.",

keywords = "Bisphosphonate, Drug delivery, Mesoporous, Raloxifene, Titanium",

author = "N. Harmankaya and J. Karlsson and A. Palmquist and M. Halvarsson and K. Igawa and M. Andersson and P. Tengvall",

note = "Funding Information: The authors thank the Materials Area of Advance at Chalmers University of Technology and University of Gothenburg, BIOMATCELL VINN Excellence Center of Biomaterials and Cell Therapy, and the Swedish Research Council (K2012–52X-09495-25-3 and B0603701) for providing financial support. ",

year = "2013",

month = jun,

doi = "10.1016/j.actbio.2013.02.040",

language = "English",

volume = "9",

pages = "7064--7073",

journal = "Acta Biomaterialia",

issn = "1742-7061",

publisher = "Elsevier BV",

number = "6",

}

TY - JOUR

T1 - Raloxifene and alendronate containing thin mesoporous titanium oxide films improve implant fixation to bone

AU - Harmankaya, N.

AU - Karlsson, J.

AU - Palmquist, A.

AU - Halvarsson, M.

AU - Igawa, K.

AU - Andersson, M.

AU - Tengvall, P.

N1 - Funding Information: The authors thank the Materials Area of Advance at Chalmers University of Technology and University of Gothenburg, BIOMATCELL VINN Excellence Center of Biomaterials and Cell Therapy, and the Swedish Research Council (K2012–52X-09495-25-3 and B0603701) for providing financial support.

PY - 2013/6

Y1 - 2013/6

N2 - This study tested the hypothesis that osteoporosis drug-loaded mesoporous TiO2 implant coatings can be used to improve bone-implant integration. Two osteoporosis drugs, Alendronate (ALN) and Raloxifene (RLX), were immobilized in nanoporous oxide films prepared on Ti screws and evaluated in vivo in rat tibia. The drug release kinetics were monitored in vitro by quartz crystal microbalance with dissipation and showed sustained release of both drugs. The osteogenic response after 28 days of implantation was evaluated by quantitative polymerase chain reaction (qPCR), removal torque, histomorphometry and ultrastructural interface analysis. The drug-loaded implants showed significantly improved bone fixation. In the case of RLX, stronger bone-remodelling activity was observed compared with controls and ALN-loaded implants. The ultrastructural interface analysis revealed enhanced apatite formation inside the RLX coating and increased bone density outside the ALN coating. Thus, this novel combination of a thin mesoporous TiO2 carrier matrix and appropriate drugs can be used to accelerate implant fixation in trabecular bone.

AB - This study tested the hypothesis that osteoporosis drug-loaded mesoporous TiO2 implant coatings can be used to improve bone-implant integration. Two osteoporosis drugs, Alendronate (ALN) and Raloxifene (RLX), were immobilized in nanoporous oxide films prepared on Ti screws and evaluated in vivo in rat tibia. The drug release kinetics were monitored in vitro by quartz crystal microbalance with dissipation and showed sustained release of both drugs. The osteogenic response after 28 days of implantation was evaluated by quantitative polymerase chain reaction (qPCR), removal torque, histomorphometry and ultrastructural interface analysis. The drug-loaded implants showed significantly improved bone fixation. In the case of RLX, stronger bone-remodelling activity was observed compared with controls and ALN-loaded implants. The ultrastructural interface analysis revealed enhanced apatite formation inside the RLX coating and increased bone density outside the ALN coating. Thus, this novel combination of a thin mesoporous TiO2 carrier matrix and appropriate drugs can be used to accelerate implant fixation in trabecular bone.

KW - Bisphosphonate

KW - Drug delivery

KW - Mesoporous

KW - Raloxifene

KW - Titanium

UR - http://www.scopus.com/inward/record.url?scp=84877706313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877706313&partnerID=8YFLogxK

U2 - 10.1016/j.actbio.2013.02.040

DO - 10.1016/j.actbio.2013.02.040

M3 - Article

C2 - 23467043

AN - SCOPUS:84877706313

SN - 1742-7061

VL - 9

SP - 7064

EP - 7073

JO - Acta Biomaterialia

JF - Acta Biomaterialia

IS - 6

ER -

Raloxifene and alendronate containing thin mesoporous titanium oxide films improve implant fixation to bone

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this